Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biotechnology company dedicated to developing innovative treatments for age-related neurological disorders. The company’s main product candidate is neflamapimod, an orally administered small molecule that penetrates the brain to inhibit p38MAP kinase alpha (p38α). This investigational drug is being developed to address synaptic dysfunction, a reversible aspect of neurodegenerative diseases such as dementia with Lewy bodies (DLB).
Recent achievements for CervoMed include the completion of patient enrollment in the RewinD-LB Phase 2b study, which is a critical step in evaluating neflamapimod's efficacy in treating DLB. This milestone reflects the company’s operational capability and the high engagement levels across clinical sites. CervoMed's financial health is robust, supported by a $21 million grant from the National Institutes of Health's National Institute on Aging (NIA) and a $50 million financing deal, which is expected to provide a financial runway through the end of 2025.
In terms of research and development, the company has shown significant progress. Neflamapimod has demonstrated the potential to modulate cholinergic dysfunction and degeneration in preclinical and clinical studies, thereby improving cognitive and motor tasks. The ongoing RewinD-LB trial aims to provide a clear path to market for neflamapimod by the end of 2024.
CervoMed also boasts a series of strategic updates, including the successful listing on NASDAQ and strengthening its leadership team. The company's leadership includes industry veterans like Joshua Boger, Ph.D., who serves as non-executive Chair of the Board, and John Alam, MD, the Chief Executive Officer. The company continues to publish data that reinforces neflamapimod's potential as a highly differentiated, first-to-market treatment option for patients with DLB.
CervoMed’s commitment to advancing neurological health is evident through its collaborations with academic researchers and participation in prominent scientific forums. Notably, the company’s ongoing efforts include exploring additional therapeutic applications for neflamapimod in other cholinergic dysfunction-driven neurological disorders.
With its strong financial foundation and promising clinical pipeline, CervoMed Inc. is well-positioned to make significant strides in the treatment of age-related neurological disorders, ultimately aiming to improve the quality of life for patients globally.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the upcoming Emerging Growth Conference. The company's management will deliver a virtual corporate presentation on Thursday, July 18, 2024, at 1:10 PM ET.
Investors and interested parties can access the webcast of the presentation through the provided link or via the Investor section of CervoMed's official website. This event offers an opportunity for stakeholders to gain insights into CervoMed's current projects, future plans, and potential growth prospects in the field of neurologic disorder treatments.
CervoMed (NASDAQ: CRVO) will host a virtual key opinion leader (KOL) event on July 23, 2024, at 10:00 AM ET, focusing on their Phase 2b RewinD-LB trial for neflamapimod, a treatment for dementia with Lewy bodies (DLB). The trial is fully enrolled, with topline data expected in December 2024. Esteemed speakers will include John-Paul Taylor and Ralph A. Nixon, who will discuss DLB's unmet needs, the role of the basal forebrain cholinergic system, and neflamapimod’s mechanism of action. The event will also cover the trial design, which aims to provide a clear path to market upon success. A live Q&A session will follow, moderated by CervoMed's CEO, John Alam. Registration is required to attend, and a replay will be available on CervoMed's website.
CervoMed (NASDAQ: CRVO), a clinical-stage company developing treatments for age-related neurologic disorders, announced its expected inclusion in the Russell 2000® and Russell 3000® Indexes, effective July 1, 2024.
This inclusion follows the 2024 Russell U.S. Indexes annual reconstitution, which captures the 4,000 largest U.S. stocks by market capitalization as of April 30, 2024.
CEO John Alam emphasized the importance of this milestone, citing it as a recognition of CervoMed's progress in advancing neflamapimod, a potential treatment for dementia with Lewy bodies (DLB).
The inclusion is expected to heighten awareness of CervoMed as it approaches the reporting of topline results from the Phase 2b RewinD-LB trial in December 2024.
CervoMed has completed enrollment for its Phase 2b RewinD-LB clinical trial, testing neflamapimod in patients with dementia with Lewy bodies (DLB). Topline data is expected in December 2024. This trial aims to address unmet needs in DLB treatment, targeting patients without Alzheimer’s disease (AD) co-pathology. CEO John Alam highlighted the significance of enrolling a pure DLB patient population. Kelly Blackburn, SVP of Clinical Development, noted the rapid enrollment due to high patient interest. Eligibility criteria included a DLB diagnosis, specific Clinical Dementia Rating scores, and low plasma ptau181 levels.
CervoMed (NASDAQ: CRVO) has announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder, who will also continue his role as General Counsel and Corporate Secretary, will succeed William Tanner. Tanner will remain with the company as a consultant. CEO John Alam expressed confidence in Elder's expertise in biopharmaceutical and financial operations during this critical phase. The company's RewinD-LB Phase 2b clinical trial is set to complete enrollment in Q2 2024, with efficacy results expected in Q4 2024. Elder's financial background includes roles at Diffusion Pharmaceuticals and Dechert LLP. He holds degrees from the University of Pennsylvania, Villanova University, and Tufts University.
CervoMed, a clinical-stage company developing treatments for age-related neurological disorders, reported its Q1 2024 financial results. The company is on track to complete enrollment for its RewinD-LB Phase 2b trial evaluating neflamapimod in DLB patients by 2Q 2024, with topline data expected in 4Q 2024.
CervoMed completed a private placement of up to $149.4 million in early 2Q 2024, with $50 million received upfront. Cash and cash equivalents as of March 31, 2024, were $6.4 million, excluding the private placement proceeds.
Grant revenue increased to $2.3 million for Q1 2024, while R&D expenses rose to $2.8 million due to the RewinD-LB trial. G&A expenses increased to $2.1 million due to higher operational costs following a reverse merger in August 2023. The company reported an operating loss of $2.6 million but net income of $2.5 million for Q1 2024.
FAQ
What is CervoMed Inc. focused on?
What is neflamapimod?
What is the RewinD-LB Phase 2b study?
What recent milestones has CervoMed achieved?
How is CervoMed funded?
Is neflamapimod safe?
What is the potential market impact of neflamapimod?
Who are the key leaders at CervoMed?
What are the next steps for CervoMed?
Where can I find more information about CervoMed’s clinical trials?
